ABSTRACT
Introduction
The interscalene and axillary brachial plexus blocks are common anesthetic methods for upper limb surgery [1, 2] . While ultrasound has improved the quality and safety of these peripheral nerve blocks, needle insertion and manipulation during the blocks may cause substantial discomfort that can reduce patient compliance and increase anxiety, fear and dissatisfaction with anesthesia care [3] [4] [5] [6] . To decrease pain, some practitioners infiltrate the skin with lidocaine 2% prior to the nerve block. However, this involves extra needle insertions and injections that can result in patient discomfort and increase the risk for intraneural or intravascular trauma.
Gel is used as an acoustic coupling medium for ultrasound-guided nerve blocks. Although a non-medicated water-based gel is the most common choice for this purpose, a water-based lidocaine 2% gel is also widely used, and its cost is similar to that of the non-medicated gel. When applied topically, the gel containing lidocaine may reduce discomfort during needle insertion and injection and can even be time-saving as the gel base can serve as an acoustic coupling medium for ultrasound imaging [6] [7] [8] [9] [10] . Thus lidocaine gel would eliminate the need for additional injections to infiltrate local anesthetic into the tissues and the time required to apply more sterile gel for ultrasound conduction.
This trial examined whether topical lidocaine gel 2% applied prior to an interscalene or axillary brachial plexus block provides noninferior patient comfort for the procedure compared to skin infiltration with 3cc lidocaine 2%. We hypothesized that mean pain scores during peripheral nerve block needle insertion and injection using topical lidocaine gel are no worse than mean pain scores using lidocaine infiltration by our prespecified margin of noninferiority. The effect of patient fearfulness of the block on reported pain during needle insertion and injection were also assessed. It was hypothesized that fear of the block differs between subjects given an application of gel and subjects given an infiltration with a needle. It was further hypothesized that fearfulness and pain are positively correlated.
Methods

Study design
This was a single center, noninferiority randomized controlled trial comparing analgesia during interscalene and axillary brachial plexus blocks administered for upper extremity surgery. Noninferiority trials are often performed to assist in finding new treatments that have approximately the same efficacy while offering benefits that the standard (reference) treatment may not provide [11, 12] . In this study, peripheral nerve block safety would be enhanced by eliminating the need for additional injections for infiltration that increase risks for tissue and nerve damage, hematoma and/ or patient discomfort. Moreover, since lidocaine gel can serve as an acoustic coupling medium, there is no need for additional sterile gel, which is normally used during ultrasound imaging.
This trial is registered with www.clinicaltrials.gov (NCT03206320). After local ethics committee approval (B371201628396) and informed consent, 30 adult subjects were randomized by the method of sealed envelopes in a 1:1:1 ratio to one of three groups: Group 1 subjects received 10 g (10 mL) of topical lidocaine 2% gel applied over the block needle insertion site 5 min prior to their nerve block (new treatment). Group 2 subjects received 3 mL of lidocaine 2% for skin infiltration 5 min prior to their nerve block (reference treatment). Group 3 subjects received 10 g sterile ultrasound gel prior to their nerve block, and serve to inform the analyses on level of fearfulness among subjects receiving the usual, non-medicated, non-infiltration preparation for ultrasoundguided peripheral nerve blocks.
Inclusion criteria were age 18 years or older, ASA I-III physical class and scheduled for interscalene or axillary brachial plexus block for upper limb surgery. Exclusion criteria were any contra-indication to the use of local anesthetic, existing baseline neurological deficit, inability to assess sensory distribution or communicate with staff, coagulation disorders, infection at the block site, opioid therapy, drug or alcohol abuse, or pregnancy. Staff who performed the blocks were not blinded to the treatment arm, however they did not conduct any of the subject assessments. Conversely, research associates who collected the outcome data were not permitted to view the gel application or infiltration procedures that took place 5 min prior to the blocks.
Primary outcome variables were Visual Analogue Scale (VAS) pain scores marked by the subject on a 100 mm line from 0 "no pain" to 100 "worst imaginable pain" for both needle insertion and injection. Needle insertion VAS represents the pain reported by the subject at the moment of skin puncture with the block needle. Injection VAS represents the pain reported by the subject during the injection of local anesthetic around the neural structures. As no measure of injection fear or anxiety that is suitable for use in the busy clinical setting has been validated [13] , a simple Likert scale was devised to assess fear of the nerve block procedure from "1" (no fear) to "5" (very fearful) and was reported by the subject immediately before the block procedures were initiated (gel or infiltration) to avoid confounding block pain with pain reported from the infiltration needle sticks.
Clinical procedure
Prior to performing the nerve blocks, subjects had an intravenous line placed and standard ASA monitoring was maintained throughout the procedure. No premedication was given. All blocks were performed in a designated block room outside the operating room.
The blocks were performed preoperatively using ultrasound guidance, nerve stimulator and injection pressure monitoring. Subjects were placed comfortably in a semi upright position with the head facing the contralateral side. The skin was disinfected with an alcohol solution of chlorhexidine combined with azorubicin. Group 1 received 10 g of topical lidocaine 2% gel applied as a 2-3 mm thick film over the block area for both block anesthesia and ultrasound conduction. Group 2 received a skin infiltration with 3 cc lidocaine 2% (27-gauge needle) and 10 g sterile ultrasound gel (2-3 mm thick film) for ultrasound conduction. Skin infiltration was performed to ensure coverage of the block needle insertion site. Group 3 received 10 g sterile non-medicated ultrasound gel applied as a 2-3 mm thick film over the block area for ultrasound conduction only.
For the interscalene and axillary brachial plexus blocks, the needle was inserted into the brachial plexus sheath using ultrasound and nerve stimulator guidance; evoked motor response <0.5 mA (0.1 msec) was avoided. After negative aspiration and an opening injection pressure below 15 psi, an ultrasound-guided perineural injection of 15 mL bupivacaine 0.5% was administered.
Statistical analysis
Sample size for the noninferiority comparison was based on a noninferiority margin of 25 for each primary outcome (needle insertion and injection VAS) with standard deviation of 15, Type I error (α) 0.05, and power (1-β) 0.90. If there is truly no difference between the reference and new treatment, then 21 subjects (7/ group) are required to be 90% sure that the lower limit of a onesided 95% confidence interval (or equivalently a 90% two-sided confidence interval) will be above the noninferiority limit of -25 [14, 15] . Noninferiority would be declared if the mean needle insertion and injection pain scores for lidocaine 2% gel were no worse than the mean pain scores for lidocaine 2% infiltration, within statistical variability, by a margin of 25 units. Our choice of noninferiority margin was based on the smallest effect size that lidocaine would reasonably and reliably provide when compared with placebo (normal saline) [16] . Sample size parameters were based on the lidocaine infiltration literature [17] , but the calculated size of 21 (7/group) was increased to 30 subjects (10/group) to accommodate the analyses assessing the potential impact of patient fearfulness of the block on their subjective reports of pain during needle insertion and injection.
Continuous variables are presented as mean ± standard deviation or as median [interquartile range]; nominal and ordinal (discrete) variables as n (%) or as ratios.
Lidocaine gel was deemed noninferior to lidocaine infiltration when the lower limit of the confidence interval between the new and reference treatments was above the lower noninferiority limit [18] . Noninferiority comparisons were concluded for pain during needle insertion and for pain during injection, separately.
Differences in needle insertion and injection pain scores by study group were analyzed by one-way ANOVA [19] . Group differences in fearfulness were analyzed by the Mann-Whitney U or KruskalWallis H test, as appropriate. The association of fearfulness with pain was assessed by the nonparametric correlation coefficient, tauB. P-values <0.05 were considered statistically significant. 
Results
Demographic characteristics and clinical features did not differ among the groups (Table 1 ). All nerve blocks were successful (Figure 1 ). One subject who had an interscalene block developed Horner's syndrome, which was self-limiting. Although we did not formally study the quality of ultrasound images among the groups, ultrasound anatomy was easily identified in all subjects. There was no perceptible difference in image quality. for continuous variables; n (%) for ordinal and nominal (categorical) variables. Gender, laterality, and block type are ratios. * Baseline function score from 0 (inability to do any activity with the arm) to 5 (normal activity with the arm).
The lower limit of the one-sided 95% confidence interval for the comparison of lidocaine gel with lidocaine infiltration was above the prespecified margin for noninferiority (-25) for needle insertion and injection VAS pain scores [-8.2, 95% CI lower bound -23) and 5.4 (95% CI lower bound -13), respectively] ( Figure 2 ).
Fear of block was distributed evenly across groups (Table 2) and did not differ between the two groups that received gel and the group that received skin infiltration (Mann-Whitney U p-value = 0.131). Fearfulness was positively correlated with both insertion and injection VAS (tauB = 0.337, p = 0.019 and tauB = 0.275, p = .053, respectively). Table 2 : Pain on needle insertion, pain during injection, and fearfulness during interscalene and axillary brachial plexus blocks for upper extremity surgery. Data are mean ± standard deviation. *VAS pain scores rated from 0 (no pain) to 100 (worst imaginable pain); p-values from 1-way ANOVA. **Fearfulness rated from 1 (no fear) to 5 (very fearful); p-value from Kruskal-Wallis test by ranks.
Discussion
Noninferiority trials are often performed to help find new treatments that have approximately the same efficacy while offering benefits that the standard treatment may not [11, 12] . For instance, using lidocaine gel eliminates the need for additional injections that increase risks for tissue and nerve damage, hematoma and/ or patient discomfort. Moreover, lidocaine gel can serve as an acoustic coupling medium, thus avoiding the need for additional sterile gel, which is typically used during ultrasound imaging.
Under the conditions of our study, lidocaine 2% gel did not confer inferior analgesia to lidocaine 2% infiltration for needle insertion or for injection pain during interscalene or axillary brachial plexus blocks. Lidocaine gel could be more effective when applied for a longer period before block performance, comparable to previous studies with different topical agents [7, 9, 10, 20] .
However, this could result in its drying, and the advantage of ultrasound conduction may dissipate. Moreover, application of gel as acoustic coupling medium in the practice of peripheral nerve blocks occurs immediately prior to the procedure, i.e., less than 5 minutes before the block. Hence, although lidocaine gel could confer more skin analgesia if left for a longer period of time (e.g., 30 min or more), we chose to apply the lidocaine gel for 5 min, which is more consistent with actual clinical practice.
Our study did not compare different application times or types of ultrasound transmission gel. Other media for ultrasound transmission may be useful, as for example, Sutton et al. used hand sanitizer as an alternative to ultrasound transmission gel [21] . Currently, we are testing higher concentrations of waterbased lidocaine gel, e.g., the 5% gel that is available to examine its analgesic effect on needle insertion and injection pain.
Conclusion
Lidocaine 2% gel is noninferior for analgesia during interscalene and axillary brachial plexus blocks compared to infiltration with lidocaine 2% while eliminating the need for additional injections.
